Trials / Completed
CompletedNCT00287183
6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multicenter Study In Patients With Type 2 Diabetes And Persistent Albuminuria To Evaluate The Safety And Efficacy Of A Six Month Regimen Of Orally-Administered TTP488
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 31 Years
- Healthy volunteers
- Not accepted
Summary
Current research indicates that TTP488 may be a viable agent for the treatment of diabetic nephropathy. The purpose of this study is to determine the safety and efficacy of a six-month regimen of daily orally-administered TTP488 to patients with diabetic nephropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-04494700 (TTP488) | 60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2006-02-06
- Last updated
- 2009-10-01
Locations
19 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00287183. Inclusion in this directory is not an endorsement.